Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Barbara Konkle, MD, K John Pasi, David J Perry, Johnny Mahlangu, Savita Rangarajan, Simon A Brown, Hideji Hanabusa, Ingrid Pabinger, Lynda M Cristiano, Elisa Tsao, Bent Winding, Desilu Glazebrook, Stefan Lethagen, Shannon Jackson

Blood (2016) 128 (22): 1413.

https://doi.org/10.1182/blood.V128.22.1413.1413

Published: 2016

Journal Articles

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Michael Wang, MD, K John Pasi, Ingrid Pabinger, Prof, Bryce A. Kerlin, Roshni Kulkarni, MD, Beatrice Nolan, Raina Liesner, Simon A Brown, Hideji Hanabusa, Elisa Tsao, Bent Winding, Stefan Lethagen, Nisha Jain

Blood (2016) 128 (22): 3791.

https://doi.org/10.1182/blood.V128.22.3791.3791

Published: 2016

Journal Articles

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Elena Santagostino, Uri Martinowitz, Toshko Lissitchkov, Brigitte Pan-Petesch, Hideji Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Negrier, Ingrid Pabinger, Mario von Depka Prondzinski, Carmen Altisent, Giancarlo Castaman, Koji Yamamoto, Maria-Teresa Álvarez-Roman, Christine Voigt, Nicole Blackman, Iris Jacobs

Blood (2016) 127 (14): 1761–1769.

https://doi.org/10.1182/blood-2015-09-669234

Published: 2016

Includes: Supplemental data

Journal Articles

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

K John Pasi, David J Perry, Johnny Mahlangu, Barbara A Konkle, MD, Savita Rangarajan, Simon Brown, Hideji Hanabusa, Shannon Jackson, Ingrid Pabinger, Lynda M Cristiano, Yingwen Dong, Elisa Tsao, Glenn F Pierce, Geoffrey Allen

Blood (2015) 126 (23): 1087.

https://doi.org/10.1182/blood.V126.23.1087.1087

Published: 2015

Journal Articles

Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Bryce A. Kerlin, Roshni Kulkarni, Beatrice Nolan, Michael Wang, MD, K John Pasi, Raina Liesner, Simon Brown, Hideji Hanabusa, Ingrid Pabinger-Fasching, Elisa Tsao, Geoffrey Allen

Blood (2015) 126 (23): 3520.

https://doi.org/10.1182/blood.V126.23.3520.3520

Published: 2015

Journal Articles

Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

Keiji Nogami, MD PhD, Masashi Taki, MD PhD, Tadashi Matsushita, MD PhD, Shouichi Ohga, MD PhD, Hideji Hanabusa, Toshiaki Oka, MD, Yasuo Horikoshi, MD, Kagehiro Amano, MD PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3526.

https://doi.org/10.1182/blood.V126.23.3526.3526

Published: 2015

Journal Articles

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Guy Young, MD, Peter W. Collins, MD, Ramin Tehranchi, MD, PhD, Ampaiwan Chuansumrit, Hideji Hanabusa, MD, Steven R. Lentz, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, MD PhD, Turkan Patiroglu, MD, Elena Santagostino, MD PhD, Marek Zak, Fara Abdul Karim

Blood (2014) 124 (21): 2846.

https://doi.org/10.1182/blood.V124.21.2846.2846

Published: 2014

Journal Articles

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Midori Shima, MD PhD, Hideji Hanabusa, MD, Masashi Taki, MDPhD, Tadashi Matsushita, MD PhD, Tetsuji Sato, MD, Katsuyuki Fukutake, MD PhD, Naoki Fukazawa, Shingo Maisawa, Koichiro Yoneyama, Keiji Nogami, MD PhD

Blood (2014) 124 (21): 691.

https://doi.org/10.1182/blood.V124.21.691.691

Published: 2014

Journal Articles

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

Manuel Carcao, MD MSc, Marek Zak, Fara Abdul Karim, Hideji Hanabusa, MD, Susan Kearney, Meng-Yao Lu, Paula Persson, Savita Rangarajan, Elena Santagostino, MD PhD

Blood (2014) 124 (21): 1513.

https://doi.org/10.1182/blood.V124.21.1513.1513

Published: 2014

Journal Articles

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood (2014) 123 (3): 317–325.

https://doi.org/10.1182/blood-2013-10-529974

Published: 2014

Includes: Supplemental data

Journal Articles

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Takashi Suzuki, MD, PhD, Katsuyuki Fukutake, MD, PhD, Kagehiro Amano, MD, PhD, Hideji Hanabusa, MD, Masashi Taki, MD, PhD, Tadashi Matsushita, MD, PhD, Midori Shima, MD, PhD, Michio Sakai, MD, PhD, Masahiro Iizuka, Yoshiyuki Shibasaki

Blood (2012) 120 (21): 3378.

https://doi.org/10.1182/blood.V120.21.3378.3378

Published: 2012

NARROW

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only